Evaluation of Ropivacaine and 3-OH-Ropivacaine Pharmacokinetics Following Interpectoral Nerve Block via LC-MS/MS—A Pilot Study
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26146696 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Mihaela Butiulca und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesiology and Intensive Care Medicine, Faculty of General Medicine, George Emil Palade University of Medicine, Pharmacy, Science,…. Hauptthemen laut MEDLINE: Ropivacaine, Nerve Block, Anesthetics, Local. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the University of Medicine, Pharmacy, Science and Technology "George Emil Palade" of Targu Mures, University of Medicine, Pharmacy, Science and Technology “George Emil Palade” of Targu Mures, Romania.
Abstract (Originalsprache)
Regional anesthesia techniques such as the ultrasound-guided PECS II (pectoral nerve block) block are increasingly employed to optimize perioperative analgesia while minimizing systemic anesthetic exposure. Ropivacaine is commonly used for its favorable pharmacological profile; however, clinical data on its pharmacokinetics and systemic metabolite behavior following interpectoral administration remain limited. This study aimed to characterize the plasma concentration–time profile of ropivacaine and its main active metabolite, 3-OH-ropivacaine, in patients undergoing interpectoral nerve block, using a validated LC-MS/MS (liquid chromatography coupled with mass spectrometry) method. Venous blood samples were collected from 18 patients at predefined time points (0, 1, 3, 6, and 24 h) following a PECS II block performed with a ropivacaine-lidocaine mixture. Plasma concentrations were quantified via a validated LC-MS/MS protocol in accordance with FDA (Food and Drug Administration) and EMA (European Medicines Agency) guidelines. Pharmacokinetic parameters were derived using non-compartmental analysis. Ropivacaine reached a mean peak plasma concentration (Cmax—maximum concentration) of 167.5 ± 28.3 ng/mL at 1.3 ± 0.2 h (Tmax—maximum time). The metabolite 3-OH-ropivacaine peaked at 124.1 ± 21.4 ng/mL at 2.3 ± 0.3 h. The terminal elimination half-life was 19.4 ± 2.8 h for ropivacaine and 29.2 ± 3.1 h for its metabolite. Plasma levels demonstrated prolonged systemic exposure with predictable pharmacokinetics. The PECS II block using ropivacaine results in sustained systemic levels of both the parent drug and its primary metabolite, supporting its role in prolonged perioperative analgesia. These data provide a pharmacokinetic foundation for personalized regional anesthesia protocols. This strategy facilitates the adaptation of anesthetic protocols to the individual characteristics of each patient, aligning with the principles of personalized medicine, particularly in patients with altered metabolic capacity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anaesthesiology and Intensive Care Medicine, Faculty of General Medicine, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania.
- Department of Anaesthesiology and Intensive Care Medicine, Emergency County Hospital, 540136 Targu Mures, Romania.
- Chromatography and Mass Spectrometry Laboratory, Center for Advanced Medical and Pharmaceutical Research, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures,…
- Department of Analytical Chemistry and Drug Analysis, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania.
- Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania.
- Department of Pharmaceutic Technology and Biopharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
ORCID-Profile: Mihaela Butiulca, Lenard Farczadi, Laurian Vlase, Leonard Azamfirei
Förderung
- the University of Medicine, Pharmacy, Science and Technology "George Emil Palade" of Targu Mures
- University of Medicine, Pharmacy, Science and Technology “George Emil Palade” of Targu Mures, Romania
Zitieren
APA
Butiulca, M., Farczadi, L., Imre, S., Vari, C. E., Vlase, L., Azamfirei, L., & Lazar, A. E. (2025). Evaluation of Ropivacaine and 3-OH-Ropivacaine Pharmacokinetics Following Interpectoral Nerve Block via LC-MS/MS—A Pilot Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26146696
Vancouver
Butiulca M, Farczadi L, Imre S, Vari CE, Vlase L, Azamfirei L, et al. Evaluation of Ropivacaine and 3-OH-Ropivacaine Pharmacokinetics Following Interpectoral Nerve Block via LC-MS/MS—A Pilot Study. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26146696
BibTeX
@article{Butiulca2025,
author = {Butiulca, Mihaela and Farczadi, Lenard and Imre, Silvia and Vari, Camil Eugen and Vlase, Laurian and Azamfirei, Leonard and Lazar, Alexandra Elena},
title = {Evaluation of Ropivacaine and 3-OH-Ropivacaine Pharmacokinetics Following Interpectoral Nerve Block via LC-MS/MS—A Pilot Study},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26146696}
}
EUVIMED